CA-SYNACK
Synack, the most trusted Crowdsourced Penetration Testing company, announced today it is now both CREST Accredited for penetration testing services and a CREST Member company in the USA. This is further recognition of Synack as the market leader in delivering the most effective, efficient penetration test.
CREST is a not-for-profit accreditation and certification body that represents and supports the technical information security market. CREST was set up in 2006 in response to the clear need for more regulated professional services with known, dependable quality, and is now recognized globally as the cyber assurance body for the technical security industry. CREST has become the respected standard for penetration testing in countries across the world, where it is increasingly a mandatory requirement for companies that have the most stringent security requirements such as government and financial services. Synack has researchers in more than 60 of these countries.
“This accreditation demonstrates that Synack’s crowdsourced penetration testing follows well-established best practices while using software and the world’s best security researchers,” said Dr. Mark Kuhr, Synack CTO and co-founder. “CREST’s accreditation examination determines if an organization meets its risk assessment, technical capability, and code of conduct standards. The CREST organisation clearly understands the challenges enterprises face today in scaling their security practices, and is supporting the G2000 by accrediting Synack to support these challenges. We appreciate the acknowledgement that Synack meets all of those critical requirements.”
Synack has prioritized trust, quality and insights as critical characteristics of a penetration test. The accreditation process determines if an organization meets risk assessment, technical capability, and code of conduct standards. Relative to a traditional penetration test, Synack believes that the crowdsourced approach provides additional testing rigor, enhanced technology, and deeper visibility and control.
“The CREST accreditation provides further recognition of Synack penetration testing, offering the highest levels of technical quality and testing rigor“ said David Charlton, Synack’s Chief Product Strategist and former Head of Penetration Testing at JPMorgan Chase & Co.
Not only does CREST offer an independent, third party assessment of a company’s penetration testing capabilities, it also provides researchers with the opportunity to become CREST qualified researchers. Synack’s crowd includes CREST certified penetration testers. Synack exposes its elite, global security researcher community in 60+ countries to the benefits of CREST. CREST offers a structured entry point for penetration testers globally and could serve as a significant stepping stone to members of the Synack’s Red Team. Synack looks forward to working closely with members of its global community seeking CREST qualifications.
This accreditation is another pillar showing that Synack takes trust seriously. Companies gain intelligence and efficiency by utilizing Synack to address vulnerabilities in a more efficient and effective way while maintaining a strong security posture. Those that work with Synack and use Crowdsourced Penetration Testing for 2+ years are up to 200% more secure than those that do not or have less than a year of usage.
Today, Synack secures >$1 trillion in Fortune 500 revenue, 75% of the top credit card companies, Top 10 consulting firms and security companies, and over 50% of federal cabinet-level agencies. Synack has received awards including 2019 Cyber Defender by CB Insights, CIO Review’s 20 Most Promising Enterprise Security Solution Providers, The Software Report’s Top 25 CyberSecurity Companies, and Wealthfront’s 2019 Career-Launching Companies.
About Synack
Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005215/en/
Contact:
Ellie McCardwell, Synack Communications Email: press@synack.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom